HEXALEN
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEXALEN is an oral small-molecule anticancer agent approved in 1990 for treating ovarian cancer and other malignancies. The drug's exact mechanism of action and pharmacologic class are not disclosed in available data. It represents a legacy oncology asset now approaching loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with minimal active commercial momentum; expect smaller brand team focused on managed decline and market transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HEXALEN offers limited growth opportunities given its LOE-approaching lifecycle and zero currently linked open positions. Career value lies in managing mature oncology products, building cost-control expertise, and navigating competitive pressures in a declining asset.
Brand ManagerField Sales Representative
Worked on HEXALEN at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.